SANGAMO THERAPEUTICS, INC. (SGMOQ) Operating cash flow 2016–2025
SANGAMO THERAPEUTICS, INC. (SGMOQ) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$97.2MFY2025 · since FY2016: -$65.9M → -$97.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$97.2M | -44.8% |
| FY2024 | -$67.1M | +70.1% |
| FY2023 | -$224.8M | -0.5% |
| FY2022 | -$223.6M | +4.1% |
| FY2021 | -$233.3M | -237.3% |
| FY2020 | $169.9M | +217.6% |
| FY2019 | -$144.4M | -495.1% |
| FY2018 | $36.5M | +227.0% |
| FY2017 | $11.2M | +117.0% |
| FY2016 | -$65.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SGMOQ financial trends
SGMOQ RevenueSGMOQ Net incomeSGMOQ Net marginSGMOQ Gross profitSGMOQ Gross marginSGMOQ Operating incomeSGMOQ Operating marginSGMOQ Free cash flowSGMOQ Capital expendituresSGMOQ Return on equitySGMOQ Stock buybacksSGMOQ Dividends paidSGMOQ Total assetsSGMOQ Total liabilitiesSGMOQ Shareholders’ equitySGMOQ overview →